Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11057750 | 0.83 | AKR1B1 (0.57) | MAOAMAOBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL11217585 | 0.82 | ALDH1A1 (0.47) | MAOAMAOBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10606255 | 0.80 | MAPT (0.42) | MAOAMAOBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL246198 | 0.79 | ALDH1A1 (0.45) | MAPTALDH1A1SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL7835016 | 0.78 | ADORA2A (0.51) | MAOAMAOBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL9870431 | 0.78 | AKR1B1 (0.46) | MAOAMAOBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10447390 | 0.78 | MAOA (0.57) | MAOAMAOBMAPTALDH1A1KDM4E | |
| SCHEMBL10606249 | 0.75 | ALDH1A1 (0.40) | MAOAMAOBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL17877029 | 0.75 | KDM4E (0.45) | MAOAMAOBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL86392 | 0.75 | MAPT (0.67) | MAOAMAOBMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393797-B1 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZACH SYSTEM SPA (IT) | 2016-04-20 | — | — | EP | disclosed |
| US-8835655-B2 | Process for preparing olopatadine and/or a pharmaceutically acceptable salt thereof | ZACH SYSTEM S.P.A (IT) | 2014-09-16 | — | — | US | disclosed |
| US-20120016138-A1 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZACH SYSTEM S.P.A. (IT) | 2012-01-19 | — | — | US | disclosed |
| EP-2393797-A2 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZaCh System S.p.A. (IT) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010089268-A2 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZACH SYSTEM S.P.A. (IT) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016138-A1 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | QDPR, OPRD1, O60361 | MAOA 39/4885MAOB 5/4885MAPT 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.